CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Ribociclib|OTHER: Endocrine therapy
Sponsor: Massachusetts General Hospital
Collaborators: Novartis